Influence of Co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation

American Journal of Transplantation

Volumn 5, Issue 12, 2005, Pages 2937-2944

  Cattaneo, D ^a,b   Merlini, S ^a,b   Zenoni, S ^a,b   Baldelli, S ^a,b   Gotti, E ^a   Remuzzi, G ^a,b   Perico, N ^a,b  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b Center for Research on Organ Transplant 'Chiara Cucchi de Alessandri and Gilberto Crespi'   (Italy)

Author keywords

Cyclosporine; Drug drug interactions; Kidney transplantation; Mycophenolic acid; Pharmacokinetics; Sirolimus

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RAPAMYCIN; CYCLOSPORIN; DRUG DERIVATIVE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG MONITORING; ENTEROHEPATIC CIRCULATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ITALY; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG INTERACTION; GRAFT REJECTION; LIVER; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CYCLOSPORINE; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS;

EID: 33644824716     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.01107.x     Document Type: Article

References (33)

1. Sollinger HW. Mycophenolates in transplantation. Clin Transplant 2004 18 : 485 492.
2. Cattaneo D Gaspari F Ferrari S et al. Pharmacokinetics helps optimizing mycophenolate mofetil dosing in kidney transplant recipients. Clin Transplant 2001 15 : 402 409.
3. Hale MD Nicholls AJ Bullingham RE et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998 64 : 672 683.
4. Bullingham RE Nicholls A Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): A short review. Transplant Proc 1996 28 : 925 929.
5. van Gelder T Hilbrands LB Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral MMF for the prevention of acute rejection after kidney transplantation. Transplantation 1999 68 : 261 266.
6. Yamani MH Starling RC Goormastic M et al. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation 2000 69 : 2326 2330.
7. van Besouw NM van der Mast BJ Smak Gregoor PJ et al. Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol Dial Transplant 1999 14 : 2710 2713.
8. Mourad M Malaise J Chaib Eddor D et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001 47 : 88 94.
9. Fulton B Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996 51 : 278 298.
10. Bullingham RE Nicholls AJ Kamm BR. Clinical Pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998 34 : 429 455.
11. Shipkova M Strassburg CP Braun F et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 2001 132 : 1027 1034.
12. Cattaneo D Perico N Gaspari F Gotti E Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002 62 : 1060 1067.
13. Zucker K Rosen A Tsaroucha A et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997 5 : 225 232.
14. Filler G Zimmering M Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000 14 : 100 104.
15. Zucker K Tsaroucha A Olson L Esquenazi V Tzakis A Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acd glucuronidation. Ther Drug Monit 1999 21 : 35 43.
16. Smak Gregoor PJ van Gelder T Hesse CJ van der Mast BJ van Besouw NM Weimar W. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: A cross-sectional study. Nephrol Dial Transplant 1999 14 : 706 708.
17. van Gelder T Klupp J Barten MJ Christians U Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001 23 : 119 128.
18. Hesselink DA van Hest RM Mathot RAA et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005 5 : 987 994.
19. Napoli KL Taylor PJ. From beach to bedside: History of the development of sirolimus. Ther Drug Monit 2001 23 : 559 586.
20. Johnson RW. Sirolimus (Rapamune) in renal transplantation. Curr Opin Nephrol Hypertens 2002 11 : 603 607.
21. Kreis H Cisterne JM Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000 69 : 1252 1260.
22. Renders L Steinbach R Valerius T Schcklmann HO Kunzendorf U. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. Kidney Blood Press Res 2004 27 : 181 185.
23. Gaspari F Perico N Ruggenenti P et al. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 1995 6 : 257 263.
24. Cattaneo D Perico N Gaspari F. Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 2002 774 : 187 194.
25. Perico N Ruggenenti P Gaspari F et al. Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation. Transplantation 1992 54 : 56 60.
26. Schutz E Shipkova M Armostrong VW et al. Therapeutic drug monitoring of mycophenolic acid: Comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998 30 : 1185 1187.
27. Weber LT Shipkova M Armstrong VW et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002 48 : 517 525.
28. Shaw LM Sollinger HW Halloran P et al. Mycophenolate mofetil: A report of the consensus panel. Ther Drug Monit 1995 17 : 690 699.
29. Shaw LM Nicholls A Hale M et al. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 1998 31 : 317 322.
30. Pawinski T Hale M Koreka M Fitzsimmons WE Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002 48 : 1497 1504.
31. Kuypers DR Claes K Evenepoel P Maes B Vanrenterghem Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004 75 : 434 437.
32. Kuypers DR Vanrenterghem Y Squifflet JP et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003 25 : 609 622.
33. Mourad M Malaise J Chaib Eddour D et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001 47 : 1241 1248.